Cardiac transplantation has evolved into an accepted treatment for end-stage heart failure, achieving a 10-year survival rate of 52% at a major center, though long-term complications require ongoing management.
Answers are grounded in this paper and cite their sources.
Supports ongoing use of cardiac transplantation in end-stage HF; extends single-center benchmarks but leaves generalizability open.
Long-term complications of cardiac transplantation Cardiac transplantation has evolved over the past 27 years from a procedure with a one year survival of 20% to an accepted treatment for end stage heart failure with over 26 000 recipients in 251 centres around the world.' Today the one year survival at Papworth, as in most established centres, is nearly 90% and five year survival and 10 year survival are 65% and 52% respectively. The cardiac trans- plant programme at Papworth Hospital started in 1979 and 600 patients have now undergone the procedure. These patients have been closely followed at the hospital and over the years the long-term problems in this popula- tion have gradually become clear.
No takes yet. Share an insight, caveat, or question.
Parameshwar et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: